Clinical and laboratory findings for the 55 AL amyloidosis patients studied
| Characteristic . | No. . |
|---|---|
| Median age, y (range) | 57 (39-80) |
| Men/women | 37/18 |
| Median survival from diagnosis, mo (range)* | 38 (1-131+) |
| Bone marrow aspirate, % | |
| Plasma cell infiltration | 7 (median, range 2-20) |
| Serum monoclonal component, no. of patients (%) | |
| Present | 50 (91) |
| IgGλ | 17 (31) |
| IgAλ | 7 (13) |
| IgDλ | 1 (2) |
| λ light chains only | 25 (45) |
| Urine monoclonal component, no. of patients (%) | |
| Present | 47 (85) |
| IgGλ | 5 (9) |
| IgAλ | 1 (2) |
| IgGλ + free λ light chains | 1 (2) |
| IgAλ + free λ light chains | 1 (2) |
| λ light chains only | 39 (71) |
| No. of organs involved†, no. of patients (%) | |
| 1 | 21 (38) |
| 2 | 23 (42) |
| 3 | 9 (16) |
| 4 | 2 (4) |
| Therapy, no. of patients (%) | |
| Treated | 53 (96) |
| MP | 27 (49) |
| M-HDex | 5 (9) |
| HDex | 8 (15) |
| HDCT+ASCT | 8 (15) |
| Iodo-DOX | 5 (9) |
| Characteristic . | No. . |
|---|---|
| Median age, y (range) | 57 (39-80) |
| Men/women | 37/18 |
| Median survival from diagnosis, mo (range)* | 38 (1-131+) |
| Bone marrow aspirate, % | |
| Plasma cell infiltration | 7 (median, range 2-20) |
| Serum monoclonal component, no. of patients (%) | |
| Present | 50 (91) |
| IgGλ | 17 (31) |
| IgAλ | 7 (13) |
| IgDλ | 1 (2) |
| λ light chains only | 25 (45) |
| Urine monoclonal component, no. of patients (%) | |
| Present | 47 (85) |
| IgGλ | 5 (9) |
| IgAλ | 1 (2) |
| IgGλ + free λ light chains | 1 (2) |
| IgAλ + free λ light chains | 1 (2) |
| λ light chains only | 39 (71) |
| No. of organs involved†, no. of patients (%) | |
| 1 | 21 (38) |
| 2 | 23 (42) |
| 3 | 9 (16) |
| 4 | 2 (4) |
| Therapy, no. of patients (%) | |
| Treated | 53 (96) |
| MP | 27 (49) |
| M-HDex | 5 (9) |
| HDex | 8 (15) |
| HDCT+ASCT | 8 (15) |
| Iodo-DOX | 5 (9) |
MP indicates mephalan and prednisone; M-HDex, melphalan plus high-dose dexamethasone; HDex, high-dose dexamethasone; HDCT, high-dose chemotherapy; ASCT, autologous stem cell transplant; Iodo-DOX, 4”-iodo-4”-deoxydoxorubicin.
According to Kaplan and Meier.
Major organs involved are reported in Figure 6.